Pancreatic Cancer Research

ResearcherAstraZeneca (United Kingdom)Active in the last 2 years

Simon T. Barry

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-8511-0588; OpenAlex author ID A5044054725. Sources: OpenAlex.

Their work

Papers
10 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
52
Papers, trials and grants by year

2016: 2 papers · 2017: none · 2018: none · 2019: 1 paper · 2020: 1 paper · 2021: 2 papers · 2022: 2 papers · 2023: 1 paper · 2024: none · 2025: 1 paper

Papers 10

  1. KRAS Loss of Heterozygosity Promotes MAPK-Dependent Pancreatic Ductal Adenocarcinoma Initiation and Induces Therapeutic Sensitivity to MEK Inhibition. Co-author DOI 10.1158/0008-5472.can-23-2709↗
  2. Persister cell phenotypes contribute to poor patient outcomes after neoadjuvant chemotherapy in PDAC. Co-author DOI 10.1038/s43018-023-00628-6↗
  3. Method To Visualize the Intratumor Distribution and Impact of Gemcitabine in Pancreatic Ductal Adenocarcinoma by Multimodal Imaging. Co-author DOI 10.1021/acs.analchem.1c04579↗
  4. Modulation of Type I Interferon Responses to Influence Tumor-Immune Cross Talk in PDAC. Last author DOI 10.3389/fcell.2022.816517↗
  5. Targeting DNA Damage Response and Replication Stress in Pancreatic Cancer. Co-author DOI 10.1053/j.gastro.2020.09.043↗
  6. Deconstructing Pancreatic Cancer Using Next Generation-Omic Technologies-From Discovery to Knowledge-Guided Platforms for Better Patient Management. Co-author DOI 10.3389/fcell.2021.795735↗
  7. HNF4A and GATA6 Loss Reveals Therapeutically Actionable Subtypes in Pancreatic Cancer. Co-author DOI 10.1016/j.celrep.2020.107625↗
  8. The integrin αvβ6 drives pancreatic cancer through diverse mechanisms and represents an effective target for therapy. Co-author DOI 10.1002/path.5320↗
  9. CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.ccell.2016.04.014↗
  10. mTORC2 Signaling Drives the Development and Progression of Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-16-0810↗

Closest collaborators

The 25 strongest of 52 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Peter J. Bailey · 5 shared papers, 2016–2023 · strength 0.69
  2. Owen James Sansom · 5 shared papers, 2016–2025 · strength 0.47
  3. Jennifer P. Morton · 4 shared papers, 2016–2025 · strength 0.36
  4. John P. Neoptolemos · 2 shared papers, 2021–2023 · strength 0.32
  5. David Kuang-Fu Chang · 3 shared papers, 2016–2025 · strength 0.32
  6. Carlotta Cattolico · 1 shared paper, 2022 · strength 0.26
  7. Joanna L. Birch · 1 shared paper, 2025 · strength 0.20
  8. Dale M. Watt · 1 shared paper, 2025 · strength 0.20
  9. Kathy McLay · 1 shared paper, 2025 · strength 0.20
  10. Sigrid K. Fey · 1 shared paper, 2025 · strength 0.20
  11. Daniel Schreyer · 1 shared paper, 2021 · strength 0.19
  12. Aarthi Gopinathan · 2 shared papers, 2016–2022 · strength 0.15
  13. Duncan Ian Jodrell · 2 shared papers, 2016–2022 · strength 0.15
  14. Nicolas Hohmann · 1 shared paper, 2023 · strength 0.13
  15. Shigenori Ei · 1 shared paper, 2023 · strength 0.13
  16. Jingyu An · 1 shared paper, 2023 · strength 0.13
  17. Markus Wolfgang Büchler · 1 shared paper, 2023 · strength 0.13
  18. Franco Fortunato · 1 shared paper, 2023 · strength 0.13
  19. Thilo Hackert · 1 shared paper, 2023 · strength 0.13
  20. Christoph Springfeld · 1 shared paper, 2023 · strength 0.13
  21. Xu Zhou · 1 shared paper, 2023 · strength 0.13
  22. Dirk Theile · 1 shared paper, 2023 · strength 0.13
  23. Oliver Strobel · 1 shared paper, 2023 · strength 0.13
  24. Ulrike Heger · 1 shared paper, 2023 · strength 0.13
  25. Colin William Steele · 2 shared papers, 2016–2019 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.